Table 2. Geometric means of PK parameters of ripertamab and rituximab.
| Parameters | Geometric mean [CV (%)] | |
| Ripertamab (n=38) | Rituximab* (n=38) | |
| PK, pharmacokinetics; AUC, area under the concentration-time curve; AUC0−85 d, AUC from time 0 to d 85; AUC0−1 w, AUC from time 0 to week 1; AUC0−2 w, AUC from time 0 to week 2; AUC0−3 w, AUC from time 0 to week 3; AUC0−8 w, AUC from time 0 to week 8; AUC0−inf, AUC from time 0 to infinity; Cmax, maximum serum concentration; t1/2, terminal elimination half-life; Tmax, time to maximum serum concentration; CL, clearance; CV, coefficient of variation; *, rituximab refers to MabThera®. | ||
| AUC0−85 d (hr·μg/mL) | 63,448.164 (22.63) | 66,020.898 (27.38) |
| AUC0−1 w (hr·μg/mL) | 19,221.729 (15.00) | 19,859.049 (17.36) |
| AUC0−2 w (hr·μg/mL) | 30,630.996 (15.17) | 31,545.376 (17.22) |
| AUC0−3 w (hr·μg/mL) | 38,360.029 (15.74) | 39,756.863 (18.04) |
| AUC0−8 w (hr·μg/mL) | 58,355.858 (19.50) | 60,652.183 (23.88) |
| AUC0−inf (hr·μg/mL) | 67,304.617 (25.56) | 70,190.499 (32.04) |
| Cmax (μg/mL) | 217.891 (11.07) | 223.701 (19.06) |
| t1/2 (h) | 466.910 (27.85) | 475.822 (26.46) |
| Tmax (h) [median (range)] | 5.00 (4.32−11.03) | 5.24 (4.13−10.42) |
| CL (mL/h/m2) | 5.572 (25.53) | 5.343 (26.22) |